Noninferiority Trial Design: Opportunities and Challenges

被引:2
|
作者
不详
机构
[1] Department of Surgery, Section of Plastic Surgery
[2] Department of Surgery, Section of Plastic Surgery, University of Michigan, Ann Arbor, MI
来源
关键词
Clinical trial; noninferiority; noninferiority margin;
D O I
10.1016/j.jhsa.2022.08.005
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Defining treatment effectiveness is the foundation of evidence-based practice. Most studies comparing the effectiveness of treatment options involve superiority designs in which a treatment is compared against a placebo, standard care, or an alternative treatment. However, in scenarios in which it is not ethical to consider these options, noninferiority designs can be considered. Noninferiority (NI) trials aim to demonstrate that a new treatment is not unacceptably worse than a standard treatment. Noninferiority is determined relative to a noninferiority margin, which is the difference between the test and active control treatment that is not unacceptably clinically inferior. However, there are important considerations with respect to the design, analysis, and interpretation of NI studies, which differ from superiority trials. This review will outline the key components of NI trials, how to interpret the findings, and understand their nuances and potential limitations. © 2022
引用
收藏
页码:1107 / 1107
页数:1
相关论文
共 50 条
  • [1] Challenges and Opportunities in IBD Clinical Trial Design
    Dubinsky, Marla C.
    Collins, Rory
    Abreu, Maria T.
    GASTROENTEROLOGY, 2021, 161 (02) : 400 - 404
  • [2] Challenges in the Design and Interpretation of Noninferiority Trials
    Mauri, Laura
    D'Agostino, Ralph B., Sr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14): : 1357 - 1367
  • [3] Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
    Siu, Lillian L.
    Ivy, Percy
    Dixon, Erica L.
    Gravell, Amy E.
    Reeves, Steven A.
    Rosner, Gary L.
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 4950 - 4958
  • [4] Challenges in the Design, Registration, and Reporting of Noninferiority Trials
    Groenwold, Rolf H. H.
    Heerdink, Eibert R.
    Klungel, Olaf H.
    JAMA PSYCHIATRY, 2022, 79 (03) : 191 - 192
  • [5] The renal function trajectory in clinical trial design: challenges and opportunities
    Rosansky, Steven
    Glassock, Richard
    KIDNEY INTERNATIONAL, 2024, 106 (04) : 565 - 568
  • [6] Opportunities and Challenges in Mendelian Randomization Studies to Guide Trial Design
    O'Donnell, Christopher J.
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2018, 3 (10) : 967 - 967
  • [7] A critical analysis of the noninferiority design of the TALENT trial
    Saha, S.
    Kerkar, P.
    Gogtay, N. J.
    INDIAN HEART JOURNAL, 2020, 72 (01) : 52 - 54
  • [8] Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities
    Baik, Christina S.
    Rubin, Eric H.
    Forde, Patrick M.
    Mehnert, Janice M.
    Collyar, Deborah
    Butler, Marcus O.
    Dixon, Erica L.
    Chow, Laura Q. M.
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 4992 - 5002
  • [9] Taking Optogenetics into the Human Brain: Opportunities and Challenges in Clinical Trial Design
    White, Michael
    Mackay, Michael
    Whittaker, Roger G.
    OPEN ACCESS JOURNAL OF CLINICAL TRIALS, 2020, 12 : 33 - 41
  • [10] Gain in Popularity of Noninferiority Trial Design: Caveat Lector
    Vermeulen, Lee
    PHARMACOTHERAPY, 2011, 31 (09): : 831 - 832